The Straight Dope on Marijuana Pharmaceuticals

For eons, cannabis has been ingested for the treatment of common and chronic ailments, but now, the march of technology is propelling wacky tobaccy into a brave new century of pharmaceutical development. Scientists around the world are studying not only whole, smoked marijuana, but also pure extracts that would make Louis Armstrong blush. The fruits of their labors could hit European pharmacies as soon as next year.

The leading-edge cannabis pharmaceutical company is the publicly-owned British firm, GW Pharmaceuticals. Their Cannabis Based Medical Extracts (CBME) have proven extraordinarily safe and effective in relieving medical conditions such as neuropathic pain and muscle spasms with effects occurring after 15-45 minutes depending on the patient's condition.

The active ingredients in cannabis are Cannabinoids and the most potent ones are Tetrahydrocannabinol (THC) and Cannabinadiol (CBD). GWP has separated various Cannabinoids to determine which work best for specific ailments. Clinical trials have shown, for instance, that appetite was most improved with pure THC, but CBD also had an effect. They found the THC/CBD mix to work especially well for sleep improvement.

"We're seeing time and time again that CBD's have something to contribute," Dr. Ethan Russo told attendees at the recent NORML Conference in San Francisco. "I've been harping on this for years, but I think we finally have definitive proof of this concept."

While activists welcome the sublingual spray's medical efficacy, the delivery system has become fairly controversial.

The device designed for the British market is a simple spray bottle with no controls because, as Russo noted, "people over there do as they're told."

In order to gain approval by the FDA and DEA, however, GWP has developed the "Advanced Delivery System" (ADS) for the American market.

With it, the liquid or solid drug is contained in a cartridge that pops into a failsafe, access-coded device with Big Brotherish features such as a quantity monitor that reports to doctors on how high the patient is getting. "In the US, this is how it will be," Russo resignedly stated.

Dr. Lester Grinspoon, retired Professor Emeritus of Harvard Medical School, has decidedly less enthusiasm for the ADS spray device. He criticizes its controls of titration, that is, how the patient incrementally increases the dosage necessary for symptomatic relief.

"The device prevents delivery if the patient tries to take more than the physician or pharmacist has set and it also can be set so that you can't get any response during certain hours. That is not titration," he told the NORML members. "The purpose of using this cumbersome and expensive device apparently reflects a concern that patients can not accurately titrate the therapeutic amount, or a fear that they might take more than they need and experience some degree of high, always assuming that the two can easily be separated."

GW Pharmaceuticals has submitted findings for three years of research on the sublingual cannabis extract and may gain approval from the British Government by the end of this year.

On May 21st, GW Pharmaceuticals announced their exclusive agreement with German drug giant Bayer AG to market the cannabis-based extracts, which will be sold under the brand name, Sativexr.

Elsewhere, the Israeli company Pharmos has created a neuroprotective product called Dexanabinol for the treatment of head trauma and stroke, and recently gained approval from the US government for a Phase III trial in the US, the first of its kind in this country.

Data from a recent German study on smoked marijuana's effects on Tourette's Syndrome shows that ingestion of pure THC resulted in a significant improvement of tic severity. In Spain, there are studies on how compounds in marijuana alleviate certain types of brain tumors.